Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells

OBJECTIVES: Interleukin (IL)-17 signalling has been shown to be a key regulator of disease in ankylosing spondylitis (AS) with several IL-17 blockers currently clinically approved. Despite this, the role of IL-17 in bone pathology is poorly understood. This study aimed to investigate IL-17 signallin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:RMD Open
Main Authors: Shah, Mittal, Maroof, Asher, Gikas, Panos, Mittal, Gayatri, Keen, Richard, Baeten, Dominique, Shaw, Stevan, Roberts, Scott J
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Spondyloarthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7722278/
https://ncbi.nlm.nih.gov/pubmed/32723833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2020-001306
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados